Capillary Technologies IPO: GMP, Details & Should You Apply?

I still remember the night before the Zomato IPO listing — I was glued to my screen, refreshing the GMP tracker every 10 minutes, convinced I was about to make a killing. I applied, got allotted, and did fine. But the Capillary Technologies IPO? Honestly, this one made me slow down and think harder than I have in a while.

If you’ve been searching for Capillary Technologies IPO details — GMP, price band, allotment, subscription status — you’ve landed in the right place. In this post, I’ll walk you through everything you need to know in plain language, no financial jargon rabbit holes. Let’s get into it.

At a Glance: Capillary Technologies IPO Quick Summary

My Personal Experience Tracking This IPO

I follow roughly 30–40 IPOs every year on Tecksslaash, and I’ve built a habit of tracking the GMP from Day 1. With Capillary Technologies, the GMP started at a flat ₹0 when the issue opened on November 14 — which made a lot of my readers nervous and start dropping messages asking, “Soyaeb bhai, apply karein ya nahi?”

Here’s the thing I’ve learned the hard way: a flat GMP at open is not always a red flag. Sometimes it just means the grey market hasn’t warmed up yet, especially for SaaS companies that attract institutional money more than retail speculators. And that’s exactly what happened here. By November 19, the GMP had jumped to a high of ₹63, which translated to roughly a 10.9% expected listing gain over the issue price of ₹577.

The lesson I took away — and one I keep sharing with our community — is this: don’t judge an IPO’s potential by its Day 1 GMP alone. Watch the subscription numbers. If QIBs (the smart institutional money) are piling in heavily, that tells you a lot more.

In this case, QIBs subscribed 57.30x, NIIs went 69.85x, and even retail clocked 15.85x by Day 3. That’s a signal the institutional crowd has done its homework.

Read More: Vedam School of Technology: Fees, Admissions & Campus Guide

What Does Capillary Technologies Actually Do?

Before you put ₹14,425 into any IPO, you should at least understand what the company does. Fair enough?

Capillary Technologies is a Bengaluru-based SaaS company founded in 2008. They build AI-powered cloud software that helps large brands run loyalty programs and customer engagement campaigns. Think of them as the engine behind those “earn points on every purchase” programs that big retailers, FMCG giants, and banks run.

Their core product suite includes:

• Loyalty+ — enterprise loyalty management
• Engage+ — personalized marketing automation (SMS, email, push)
• Insights+ — AI-driven customer analytics
• Rewards+ — reward catalog and redemption management
• CDP (Customer Data Platform) — unified customer data layer

As of September 2025, they served over 410 brands across 47 countries, including 19 Global Fortune 500 companies. Some notable clients include Aditya Birla Fashion & Retail, Tata Digital, Frontier Communications, and Abbott Laboratories.

North America brings in 56% of their revenue, followed by Asia-Pacific at 25% and EMEA at 19%. So this isn’t just an India-focused story — it’s a genuinely global business.

Capillary Technologies IPO GMP Today — What It Means

Let’s talk GMP specifically, because it’s the most searched thing about this IPO.

GMP (Grey Market Premium) is essentially what people are willing to pay for IPO shares in unofficial, off-market trades before the stock is formally listed. It gives you a rough idea of listing sentiment — but it’s not a guarantee of anything.

Here’s how the GMP moved for Capillary Technologies:

At ₹60 GMP over an issue price of ₹577, the expected listing price was around ₹637 — roughly a 10.4% listing gain for allottees. That’s a decent short-term number, but given the high valuation of the stock, I personally wouldn’t chase it in the secondary market on listing day.

Capillary Technologies IPO: Financials You Should Know

This is where things get interesting — and a little concerning.

The company turned profitable for the first time in FY25 with a net profit of ₹14.15 crore. Revenue grew 14% year-on-year and PAT jumped 121% from FY24 to FY25. Those are solid growth numbers.

But here’s the catch: At the upper price band of ₹577, the stock is valued at a P/E multiple of roughly 323x its FY25 earnings. That’s not a typo. Three hundred and twenty-three times earnings.

For comparison:

Now, high P/E in SaaS isn’t unusual for high-growth companies. The market is essentially betting on future earnings, not past ones. But 323x is aggressive even by SaaS standards. There’s very little margin for error — one weak quarter, one large client churning, and the stock could correct sharply.

That said, a few things are genuinely impressive: 121% Net Revenue Retention (NRR), which means existing customers are spending more over time, is actually better than HubSpot’s 102%. Recurring subscription revenue makes up 89% of total revenue, which is excellent for predictability.

Capillary Technologies IPO Allotment — How to Check Status

The allotment for Capillary Technologies IPO was finalized on November 19, 2025, and shares were credited to demat accounts by November 20, 2025.

To check your allotment status:

1. Visit the BSE IPO allotment page or the MUFG Intime registrar portal
2. Select “Capillary Technologies” from the dropdown
3. Enter your PAN number or application number
4. Check your status

If you were allotted shares, the listing date was November 21, 2025 on both BSE and NSE. Given the GMP at that point, most retail allottees had a reasonable short-term profit opportunity.

Common Mistakes Investors Make With IPOs Like This

I’ve seen these play out in our comment section and on investing forums too many times, so let me save you some pain.

Mistake 1: Applying purely based on GMP GMP is unofficial, unregulated, and can move wildly in 24 hours. Capillary’s GMP was ₹0 on Day 1 and ₹63 near allotment. If you had avoided applying because of the flat GMP, you’d have missed a decent listing gain.

Solution: Use GMP as one signal, not the only signal. Check subscription status and institutional interest.

Mistake 2: Confusing “first-time profitability” with “strong profitability” Capillary turned profitable in FY25 — yes. But ₹14.15 crore in net profit on ₹598 crore revenue is a thin margin. At 323x P/E, you’re paying a huge premium for future potential that hasn’t materialized yet.

Solution: Look at absolute profit numbers, not just the growth percentage. 121% PAT growth sounds amazing, but it went from near-zero.

Mistake 3: Ignoring the OFS component More than 60% of this IPO is an Offer for Sale — meaning the promoters and investors are cashing out, not raising fresh capital for growth. Only ₹345 crore of the ₹877.5 crore will actually go into the company.

Solution: Always check the split between fresh issue and OFS before applying.

Mistake 4: Holding for too long after a flat listing If a high-P/E stock doesn’t get the listing pop you expected, don’t anchor to your hopes. Have an exit strategy before you apply.

Solution: Decide your exit price before allotment — not after you see the listing candle.

Should You Apply? My Honest Take

Look, I’m not a SEBI-registered advisor and nothing I say here is investment advice. But as someone who has tracked hundreds of IPOs and lived through both the euphoria and the heartbreak — here’s my read:

For listing gain hunters: The GMP near allotment suggested a 10–11% potential pop. That’s not bad for a 3-day block of funds. But the subscription was 53x, which means competition for allotment is intense.

For long-term investors: The company has a genuinely interesting position in global enterprise loyalty management with a growing SaaS model and strong retention metrics. If India’s SaaS sector grows toward the projected $50–70 billion by 2030, companies like Capillary could benefit significantly. But the valuation means you need a 3+ year horizon and patience through near-term volatility.

For cautious investors: The aggressive P/E, thin current profitability, and a heavily OFS-driven IPO structure are real concerns. SBI Securities and Swastika Investmart both recommended ‘Avoid’ at the valuation. That’s worth noting.

My personal approach? I applied for listing gain potential, given the strong institutional subscription. But I wasn’t going to hold post-listing at 323x earnings. That’s just me — your situation, risk appetite, and goals may be completely different.

Frequently Asked Questions

Conclusion: My Final Verdict

The Capillary Technologies IPO is genuinely one of the more interesting SaaS listings India has seen in a while — a global business, strong client retention, and real recurring revenue. But the valuation is aggressive, the OFS component is heavy, and the first-time profitability is thin at the current price.

If you got allotted — congratulations. The GMP near listing suggests a decent short-term opportunity. If you’re thinking of buying from the secondary market after listing: wait, watch, and see how the stock stabilizes before jumping in. Chasing a SaaS stock at 323x P/E without a clear growth catalyst is a risk I’d personally avoid.

As always, do your own research and never invest money you can’t afford to lock up for a while.

What do you think about the Capillary Technologies IPO? Are you in it for the listing pop or holding for the long term? Drop your thoughts in the comments below — I read every single one!

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.